ACCELERON PHARMA INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Operating Activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposition of property and equipment
Stock-based compensation
Accretion of deferred interest
Amortization of deferred debt issuance costs
Change in fair value of warrants
Net amortization of premium on investments
Other non-cash items
Changes in assets and liabilities:
Prepaid expenses and other current assets
Collaboration receivables
Non-cash lease expense
Accounts payable
Accrued expenses
Deferred revenue
Deferred rent
Restricted cash
Operating lease obligations
Other changes in operating assets and liabilities

Net cash used in operating activities
Investing Activities
Proceeds from sales and maturities of investments
Purchase of investments
Proceeds from maturity or sale of securities
Purchases of property and equipment
Net cash provided by (used in) investing activities

Financing Activities
Payments of long-term debt
Payments for withholding taxes on restricted stock units
Proceeds from issuances of common stock related to employee stock purchase plan
Proceeds from exercise of stock options and warrants to purchase common stock
Payments for capital lease expenditures
Net proceeds from exercises and vesting of stock awards, and ESPP contributions
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Cash paid for interest
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Reclassification of warrant liability to additional paid-in capital
Capitalized follow-on public offering costs included in accrued expenses
Purchase of property and equipment included in accounts payable and accrued expenses

Comments